Drug
AMG 176
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/3)
Active Trials
0(0%)
Terminated
3(100%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 3 finished
Non-Completion Rate
100.0%
3 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Terminated(3)
Detailed Status
Terminated3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
terminated3100%
Recent Activity
0 active trials
Showing 3 of 3
terminatedphase_1
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
NCT05209152
terminatedphase_1
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
NCT02675452
terminatedphase_1
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
NCT03797261
Clinical Trials (3)
Showing 3 of 3 trials
NCT05209152Phase 1
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
NCT02675452Phase 1
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
NCT03797261Phase 1
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3